NEW YORK ( TheStreet) -- SuperGen (Nasdaq: SUPG) has been upgraded by TheStreet Ratings from hold to buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself.

Highlights from the ratings report include:
  • 42.10% is the gross profit margin for SUPERGEN INC which we consider to be strong. It has increased significantly from the same period last year. Along with this, the net profit margin of 44.10% significantly outperformed against the industry average.
  • Current return on equity exceeded its ROE from the same quarter one year prior. This is a clear sign of strength within the company. Compared to other companies in the Biotechnology industry and the overall market, SUPERGEN INC's return on equity exceeds that of both the industry average and the S&P 500.
  • SUPG has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 19.06, which clearly demonstrates the ability to cover short-term cash needs.
  • The revenue growth greatly exceeded the industry average of 3.2%. Since the same quarter one year prior, revenues rose by 27.7%. This growth in revenue appears to have trickled down to the company's bottom line, improving the earnings per share.

Supergen, Inc., a pharmaceutical company, primarily engages in the discovery and development of therapies to treat patients with cancer. The company has a P/E ratio of 10.8, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 21.5. SuperGen has a market cap of $176.7 million and is part of the health care sector and drugs industry. Shares are up 11.4% year to date as of the close of trading on Thursday.

You can view the full SuperGen Ratings Report or get investment ideas from our investment research center.
null

If you liked this article you might like

SuperGen Inc. Stock Downgraded (SUPG)

SuperGen Inc. Stock Downgraded (SUPG)

SuperGen's CEO Discusses Q2 2011 Results - Earnings Call Transcript

SuperGen's CEO Discusses Q2 2011 Results - Earnings Call Transcript

Acadia Pharmaceuticals: Investing With No Safety Net

Acadia Pharmaceuticals: Investing With No Safety Net

SuperGen's CEO Discusses Q1 2011 Results - Earnings Call Transcript

SuperGen's CEO Discusses Q1 2011 Results - Earnings Call Transcript